Arbios gets funding towards artificial liver trial
This article was originally published in Clinica
Executive Summary
Arbios Systems has raised $6.61m in a private placement that will enable it to prepare for a phase III trial of its bioartificial liver (BAL), HepatAssist-2. This device is an enhanced version of Circe Biomedical's HepatAssist, the rights to which Arbios reacquired last April (see Clinica No 1105, p 21). It is hoped such technology will support a patient with acute liver failure until either they receive a transplant or their own liver recovers.